EPISODE · Jan 16, 2015 · 25 MIN
Gluten and GMO: The Toxic Reality for 18 Million and Counting
from Mad Science: The Genetic Crossroad With Anna Kavanaugh · host Anna Kavanaugh | Living Eden Media, LLC
It is still a fairly new-recognized and rapidly increasing reality. Gluten intolerance has become a primary health concern for millions of consumers around the world. However, in the face of such an epidemic, the biotech industry is in aggressive pursuit of genetically manipulating a relief for this affliction, one they seek undoubtedly to capitalize on. If brought to fruition, the result of such a genetically engineered response may in actuality cause more grave consequences to consumers than it will provide them help. Revealing the latest research and what it says about gluten intolerance and the dangers involved with GM alternatives currently under development. If you are one of the millions suffering from this affliction, please don't miss out on hearing the important information brought to you in this broadcast.
What this episode covers
It is still a fairly new-recognized and rapidly increasing reality. Gluten intolerance has become a primary health concern for millions of consumers around the world. However, in the face of such an epidemic, the biotech industry is in aggressive pursuit of genetically manipulating a relief for this affliction, one they seek undoubtedly to capitalize on. If brought to fruition, the result of such a genetically engineered response may in actuality cause more grave consequences to consumers than it will provide them help. Revealing the latest research and what it says about gluten intolerance and the dangers involved with GM alternatives currently under development. If you are one of the millions suffering from this affliction, please don't miss out on hearing the important information brought to you in this broadcast.
NOW PLAYING
Gluten and GMO: The Toxic Reality for 18 Million and Counting
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m